Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine University, Düsseldorf, Germany.
Leuk Res. 2012 Aug;36(8):1067-70. doi: 10.1016/j.leukres.2012.04.006. Epub 2012 May 6.
MDS patients are prone to develop transfusional iron overload. Iron overload may partly explain why transfusion dependency is associated with a decreased likelihood of survival. Our matched-pair analysis included 94 patients on long-term chelation therapy and 94 matched patients without it. All patients had iron overload, defined as serum ferritin (SF) above 1000 ng/ml or a history of multiple transfusions and SF ≥ 500 ng/ml. Median SF was 1954 ng/ml in chelated and 875 ng/ml in non-chelated patients. The difference in median survival (74 vs. 49 months, respectively; p=0.002) supports the idea that iron chelation therapy is beneficial for MDS patients.
MDS 患者易发生输血相关性铁过载。铁过载可能部分解释了为什么输血依赖与生存率降低有关。我们的配对分析包括 94 例长期螯合治疗患者和 94 例匹配的未接受螯合治疗患者。所有患者均存在铁过载，定义为血清铁蛋白（SF）>1000ng/ml 或多次输血史和 SF≥500ng/ml。螯合组中位 SF 为 1954ng/ml，未螯合组中位 SF 为 875ng/ml。中位生存（分别为 74 个月和 49 个月；p=0.002）的差异支持铁螯合治疗对 MDS 患者有益的观点。
